Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ELX-02 study in cystic fibrosis with at least one G542X allele
2018-000966-12Phase 2Completed
- Sponsor
- Eloxx Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of exaluren and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Eloxx Pharmaceuticals. Primary endpoints: Safety and tolerability of ELX-02 and Pharmacokinetics of ELX-02. Started Jun 2019; status: completed.
02
Drugs
exalurenivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000966-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000966-12.